Valneva to participate in multiple events at the 25th world vaccine congress, including a presentation on its chikungunya vaccine ixchiq®

Saint-herblain (france), april 16, 2025 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced its presence at the forthcoming 25th world vaccine congress, which will take place from april 21-24, 2025 at the walter e. convention center in washington, d.c. under the leadership of the company´s chief executive officer, thomas lingelbach, a team of valneva´s senior managers will participate in multiple events, including an important presentation on the company´s vaccine ixchiq®, the world's first licensed chikungunya vaccine.
VALN Ratings Summary
VALN Quant Ranking